IN2014DN11205A - - Google Patents
Info
- Publication number
- IN2014DN11205A IN2014DN11205A IN11205DEN2014A IN2014DN11205A IN 2014DN11205 A IN2014DN11205 A IN 2014DN11205A IN 11205DEN2014 A IN11205DEN2014 A IN 11205DEN2014A IN 2014DN11205 A IN2014DN11205 A IN 2014DN11205A
- Authority
- IN
- India
- Prior art keywords
- compounds
- relates
- formulae
- iii
- cell lymphoma
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 5
- 208000003950 B-cell lymphoma Diseases 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 201000005787 hematologic cancer Diseases 0.000 abstract 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 abstract 2
- 108010022579 ATP dependent 26S protease Proteins 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 229940079156 Proteasome inhibitor Drugs 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 229960001467 bortezomib Drugs 0.000 abstract 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000003278 mimic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003207 proteasome inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
- G01N33/5079—Mitochondria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261662084P | 2012-06-20 | 2012-06-20 | |
PCT/US2013/046826 WO2013192423A2 (en) | 2012-06-20 | 2013-06-20 | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN11205A true IN2014DN11205A (he) | 2015-10-02 |
Family
ID=49769702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN11205DEN2014 IN2014DN11205A (he) | 2012-06-20 | 2013-06-20 |
Country Status (4)
Country | Link |
---|---|
US (3) | US20150150869A1 (he) |
EP (1) | EP2863920B1 (he) |
IN (1) | IN2014DN11205A (he) |
WO (1) | WO2013192423A2 (he) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150150869A1 (en) | 2012-06-20 | 2015-06-04 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
EP2922544B1 (en) * | 2012-11-21 | 2018-08-01 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
US20170044107A1 (en) * | 2014-04-28 | 2017-02-16 | The J. David Gladstone Institutes | Inhibitors of JMJD2C as Anticancer Agents |
MX2017013383A (es) | 2015-04-20 | 2017-12-07 | Tolero Pharmaceuticals Inc | Prediccion de respuesta a alvocidib mediante perfilado mitocondrial. |
TR201911032T4 (tr) | 2015-05-18 | 2019-08-21 | Tolero Pharmaceuticals Inc | Artırılmış biyoyararlanıma sahip alvocıdıb ön ilaçları. |
AU2016301315C1 (en) | 2015-08-03 | 2022-07-07 | Sumitomo Pharma Oncology, Inc. | Combination therapies for treatment of cancer |
WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
KR20190099260A (ko) | 2016-12-19 | 2019-08-26 | 톨레로 파마수티컬스, 인크. | 프로파일링 펩티드 및 감도 프로파일링을 위한 방법 |
WO2018222473A1 (en) | 2017-06-01 | 2018-12-06 | Albert Einstein College Of Medicine, Inc. | Bax activators and uses thereof in cancer therapy |
WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
WO2020117988A1 (en) | 2018-12-04 | 2020-06-11 | Tolero Pharmaceuticals, Inc. | Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
WO2023020534A1 (en) * | 2021-08-18 | 2023-02-23 | Nanjing Immunophage Biotech Co., Ltd | Compounds and their uses as mif inhibitors |
AU2023235233A1 (en) | 2022-03-14 | 2024-09-12 | Slap Pharmaceuticals Llc | Multicyclic compounds |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4642903A (en) | 1985-03-26 | 1987-02-17 | R. P. Scherer Corporation | Freeze-dried foam dosage form |
US4855326A (en) | 1987-04-20 | 1989-08-08 | Fuisz Pharmaceutical Ltd. | Rapidly dissoluble medicinal dosage unit and method of manufacture |
US5578322A (en) | 1990-11-30 | 1996-11-26 | Yamanouchi Pharmaceutical Co., Ltd. | Quick release coated preparation |
US5518730A (en) | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
US5380473A (en) | 1992-10-23 | 1995-01-10 | Fuisz Technologies Ltd. | Process for making shearform matrix |
DE69429119T2 (de) | 1993-07-09 | 2002-07-18 | R.P. Scherer Corp., Troy | Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen |
US5622852A (en) | 1994-10-31 | 1997-04-22 | Washington University | Bcl-x/Bcl-2 associated cell death regulator |
US5895664A (en) | 1993-09-10 | 1999-04-20 | Fuisz Technologies Ltd. | Process for forming quickly dispersing comestible unit and product therefrom |
US5616344A (en) | 1994-06-14 | 1997-04-01 | Fuisz Technologies Ltd. | Apparatus and process for strengthening low density compression dosage units and product therefrom |
US5622719A (en) | 1993-09-10 | 1997-04-22 | Fuisz Technologies Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
GB9422836D0 (en) | 1994-11-11 | 1995-01-04 | Wainscoat James | Monitoring malignant disease |
US5607697A (en) | 1995-06-07 | 1997-03-04 | Cima Labs, Incorporated | Taste masking microparticles for oral dosage forms |
WO1998009643A1 (en) | 1996-09-09 | 1998-03-12 | Washington University | Modulation of apoptosis by serine phosphorylation of blc-xl/blc-2 associated cell death regulator |
US5955593A (en) | 1996-09-09 | 1999-09-21 | Washington University | BH3 interacting domain death agonist |
US5856445A (en) | 1996-10-18 | 1999-01-05 | Washington University | Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator |
US5981201A (en) | 1997-01-08 | 1999-11-09 | Beth Israel Deaconess Medical Center | Methods of detection and treatment of breast cancer |
AU736912B2 (en) | 1997-02-20 | 2001-08-02 | Therics, Inc. | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
GB9704444D0 (en) | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
JP2001524301A (ja) | 1997-09-17 | 2001-12-04 | ザ・ワルター・アンド・エリザ・ホール・インスティテュート・オヴ・メディカル・リサーチ | 新規治療用分子 |
WO1999016787A1 (en) | 1997-09-26 | 1999-04-08 | Washington University | Cell death agonists |
US6277406B1 (en) | 1997-10-08 | 2001-08-21 | Fuisz Technologies Ltd. | Easily processed tablet compositions |
US6165732A (en) | 1997-10-14 | 2000-12-26 | Washington University | Method for identifying apoptosis modulating compounds |
US7026456B1 (en) | 1998-01-23 | 2006-04-11 | Hoffman-La Roche, Inc. | Antibodies against human IL-12 |
AU762756B2 (en) | 1998-05-18 | 2003-07-03 | Apoptosis Technology, Inc. | Compounds, screening methods, and uses involving anti-apoptotic genes and gene products |
US6326354B1 (en) | 1998-08-19 | 2001-12-04 | Washington University | Modulation of apoptosis with bid |
EP1104460A1 (en) | 1998-08-19 | 2001-06-06 | Washington University | Modulation of apoptosis with bid |
WO2002005835A2 (en) | 2000-07-17 | 2002-01-24 | Washington University | Modulation of apoptosis |
CN1493159A (zh) | 2000-12-28 | 2004-04-28 | ��ķɭ��ɹ�˾ | 作为诊断辅助的屏上显示 |
US20020177692A1 (en) | 2001-04-16 | 2002-11-28 | Myriad Genetics, Incorporated | BCL-XL-interacting protein and use thereof |
EP1436406A4 (en) | 2001-09-24 | 2004-10-13 | Blood Ct Res Foundation | METHOD FOR MODULATING OR EXAMINING THE KU70 MIRROR IN CELLS |
US7247700B2 (en) | 2001-12-31 | 2007-07-24 | Dana Farber Cancer Institute, Inc. | BID polypeptides and methods of inducing apoptosis |
CA2496400A1 (en) | 2002-09-09 | 2004-03-18 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
JP4480674B2 (ja) | 2002-12-26 | 2010-06-16 | ザクリトエ アクツィオネルノエ オブシェストヴォ “エフロージェン” | コペポーダ種由来の蛍光たんぱく質および該たんぱく質の使用方法 |
WO2004066958A2 (en) | 2003-01-30 | 2004-08-12 | The Trustees Of Princeton University | Caspase-9:bir3 domain of xiap complexes and methods of use |
TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
JP2006519846A (ja) | 2003-03-10 | 2006-08-31 | シェーリング コーポレイション | 複素環式キナーゼインヒビター:使用および合成の方法 |
US7755765B2 (en) | 2003-03-17 | 2010-07-13 | Massachusetts Institute Of Technology | Method and apparatus for inertial sensing via measurement of trapped orbit dynamics |
CA2521082A1 (en) | 2003-04-01 | 2004-10-28 | Monogram Biosciences, Inc. | Surface receptor complexes as biomarkers |
FR2855650B1 (fr) | 2003-05-30 | 2006-03-03 | Soitec Silicon On Insulator | Substrats pour systemes contraints et procede de croissance cristalline sur un tel substrat |
CN1302004C (zh) | 2003-08-22 | 2007-02-28 | 浙江海正药业股份有限公司 | 一种阿糖胞苷的制备方法 |
PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
CN1906209A (zh) | 2003-11-05 | 2007-01-31 | 达纳-法伯癌症研究所股份有限公司 | 稳定的α螺旋肽及其用途 |
GB0326964D0 (en) | 2003-11-19 | 2003-12-24 | Glaxo Group Ltd | Chemical compounds |
ES2550614T3 (es) | 2004-04-09 | 2015-11-11 | Genomic Health, Inc. | Marcadores de expresión génica para predecir la respuesta a la quimioterapia |
WO2007123791A2 (en) | 2006-03-31 | 2007-11-01 | Dana-Farber Cancer Institute | Methods of determining cellular chemosensitivity |
WO2008021484A2 (en) | 2006-08-16 | 2008-02-21 | Eutropics Pharmaceuticals | Assay system to identify therapeutic agents |
PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
WO2009004427A2 (en) | 2007-06-29 | 2009-01-08 | Pfizer Inc. | Benzimidazole derivatives |
US20090030005A1 (en) | 2007-07-19 | 2009-01-29 | Amgen Inc. | Combinations for the treatment of cancer |
AU2008335772B2 (en) | 2007-12-10 | 2014-11-27 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3- methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1- (2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
EP2304047A4 (en) | 2008-05-07 | 2012-12-26 | Eutropics Pharmaceuticals Inc | ANTIBODIES TAKEN UPON HETERODIMES OF THE BCL-2 FAMILY AND THEIR USES |
US20100015058A1 (en) | 2008-06-25 | 2010-01-21 | Stanford University | Radiolabeled bbn-rgd heterodimers for cancer targeting |
CN102239149B (zh) * | 2008-10-06 | 2015-05-13 | 约翰·霍普金斯大学 | 喹啉化合物作为血管新生、人类甲硫氨酰氨肽酶、以及sirt1的抑制剂,以及治疗病症的方法 |
CN102388151A (zh) | 2009-02-11 | 2012-03-21 | 雅培制药有限公司 | 用于鉴定、分类和监控具有bcl-2家族抑制剂抗性肿瘤和癌症的受试者的方法和组合物 |
JP2012520887A (ja) | 2009-03-18 | 2012-09-10 | シェーリング コーポレイション | ジアシルグリセロールアシルトランスフェラーゼの阻害剤としての二環式化合物 |
WO2010114922A1 (en) | 2009-03-31 | 2010-10-07 | Agios Pharmaceuticals, Inc. | Methods of treating cancer having an aberrant egfr or kras genotype |
NZ596468A (en) | 2009-05-14 | 2013-11-29 | Nestec Sa | Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy |
FI2440546T3 (fi) * | 2009-06-12 | 2023-03-30 | Abivax | Ennenaikaisen vanhenemisen ja erityisesti progerian hoitamiseen hyödyllisiä yhdisteitä |
JP2013502399A (ja) * | 2009-08-20 | 2013-01-24 | ヴィフォール (インターナショナル) アクチェンゲゼルシャフト | 新規なキノリン系ヘプシジン拮抗薬 |
EP2521553A4 (en) * | 2010-01-06 | 2013-08-28 | Errico Joseph P | METHODS AND COMPOSITIONS FOR THE DEVELOPMENT OF TARGETED MEDICAMENTS |
WO2011088137A2 (en) | 2010-01-12 | 2011-07-21 | H. Lee Moffitt Cancer Center & Research Institute | Bad pathway gene signature |
WO2011094708A2 (en) * | 2010-01-29 | 2011-08-04 | Dana-Farber Cancer Institute, Inc | Small molecules for the modulation of mcl-1 and methods of modulatiing cell death, cell division, cell differentiation and methods of treating disorders |
US8785490B2 (en) * | 2010-04-09 | 2014-07-22 | University Of Louisville Research Foundation, Inc. | Compounds for treating disease, for administering, and for pharmaceutical compositions |
EP2596366A4 (en) * | 2010-07-21 | 2014-04-16 | Joseph P Errico | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS |
US8716295B2 (en) | 2010-10-27 | 2014-05-06 | Yves Pommier | Fluoroquinolone derivatives or sulfonamide moiety-containing compounds as inhibitors of tyrosyl-dnaphosphodiesterase (TDP1) |
WO2012122370A2 (en) | 2011-03-08 | 2012-09-13 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
US20150150869A1 (en) | 2012-06-20 | 2015-06-04 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
EP2863922A4 (en) | 2012-06-20 | 2015-11-04 | Univ Vanderbilt | SUBSTITUTED BICYCLIC ALKOXYPYRAZOL ANALOGUES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS |
EP2922544B1 (en) | 2012-11-21 | 2018-08-01 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
-
2013
- 2013-06-20 US US14/409,789 patent/US20150150869A1/en not_active Abandoned
- 2013-06-20 US US14/410,399 patent/US20150133450A1/en active Pending
- 2013-06-20 EP EP13806664.2A patent/EP2863920B1/en active Active
- 2013-06-20 IN IN11205DEN2014 patent/IN2014DN11205A/en unknown
- 2013-06-20 WO PCT/US2013/046826 patent/WO2013192423A2/en active Application Filing
-
2018
- 2018-04-02 US US15/943,112 patent/US10765673B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2863920A4 (en) | 2016-07-13 |
US10765673B2 (en) | 2020-09-08 |
US20150150869A1 (en) | 2015-06-04 |
WO2013192423A3 (en) | 2015-06-25 |
EP2863920A2 (en) | 2015-04-29 |
US20150133450A1 (en) | 2015-05-14 |
US20180221366A1 (en) | 2018-08-09 |
EP2863920B1 (en) | 2023-03-22 |
WO2013192423A2 (en) | 2013-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN11205A (he) | ||
WO2012122370A3 (en) | Compositions and methods useful for treating diseases | |
MX360404B (es) | Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr. | |
EA201390756A1 (ru) | Модулирующие nk-клетки терапии и способы для лечения гематологических злокачественных заболеваний | |
IN2014CN02501A (he) | ||
PH12017502141A1 (en) | Compounds and their methods of use | |
MX2018010261A (es) | Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos. | |
MX342274B (es) | Actividades de la piruvato quinasa m2 (pkm2). | |
MY160485A (en) | Cd33 binding agents | |
BR112015011756A2 (pt) | inibidores da glutamase e métodos de uso | |
IN2012DN00471A (he) | ||
MX366804B (es) | Translocaciones de la r-espondina y sus metodos de uso. | |
NZ726671A (en) | Compounds useful as inhibitors of atr kinase and combination therapies thereof | |
NZ601065A (en) | Wnt antagonists and methods of treatment and screening | |
MX2014010713A (es) | Activacion de procaspasa 3 mediante terapia de combinacion. | |
IL207310A0 (en) | Vaccine compositions | |
NZ723971A (en) | Methods and compositions for treating ewings sarcoma family of tumors | |
NZ603952A (en) | Phosphaplatins and their use for treatment of cancers | |
MX2019011469A (es) | Inhibidores del mir-155 para tratar linfoma cutaneo de celulas t (ctcl). | |
MX2017014641A (es) | Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa). | |
MX364002B (es) | Compuestos y composiciones activadoras de enzima. | |
NZ627480A (en) | Inhibitors of iap | |
MX2013002155A (es) | Compuestos para el tratamiento de cancer. | |
IN2014MN01944A (he) | ||
MX2011006532A (es) | Compuestos anticancerigenos. |